Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. In the organ transplant setting, which it calls Facilitated Allo-HSCT Therapy, could prevent organ rejection without the morbidity. Co.'s primary product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor. We show 11 historical shares outstanding datapoints in our TALS shares outstanding history coverage, used to compute TALS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TALS market cap history over the course of time is important for investors
interested in comparing TALS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TALS versus a peer is one thing; comparing
TALS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TALS can fluctuate over the course of history.
With this page we aim to empower investors researching TALS by allowing them to research the TALS market cap history. |
Free TALS Email Alerts:
Video: The Importance of Market Cap
